BeyondSpring Receives Two Grants in China to Further Develop Innovative Drug Pipeline
October 23, 2017 08:30 ET
|
BeyondSpring, Inc.
NEW YORK, Oct. 23, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
BeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18 in San Francisco
October 18, 2017 08:30 ET
|
BeyondSpring, Inc.
NEW YORK, Oct. 18, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027: Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, Other
September 11, 2017 07:57 ET
|
Visiongain Ltd
LONDON, Sept. 11, 2017 (GLOBE NEWSWIRE) -- The Non-Small Cell Lung Cancer (NSCLC) Drugs market is estimated at $7.86bn in 2016 and is expected to grow at a CAGR of 4.9% in the first half of the...
Biothera Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA in Non-Small Cell Lung Cancer
July 19, 2017 10:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., July 19, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that the Big Ten Cancer Research Consortium has begun patient dosing in a Phase 1b/2 clinical study to...
Peregrine to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2017 After Market Close on July 14, 2017
July 07, 2017 16:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., July 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high...
Peregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred Stock
June 06, 2017 16:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend...
Peregrine Pharmaceuticals Presents Preliminary Correlative Analysis of PD-L1 Expression from SUNRISE Trial at ASCO 2017
June 05, 2017 08:05 ET
|
Peregrine Pharmaceuticals Inc.
-- Negative PD-L1 Expression was Associated with a Significantly Longer Median Overall Survival Compared to Positive PD-L1 Expression in Patients Receiving Docetaxel Plus Bavituximab -- -- Presented...
BeyondSpring to Present at the Jefferies 2017 Healthcare Conference
June 02, 2017 16:32 ET
|
BeyondSpring, Inc.
NEW YORK, June 02, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a late-stage clinical development company focused on a rich pipeline of innovative immuno-oncology cancer therapies,...
Biothera Pharmaceuticals’ Phase 2 Study of Imprime PGG Combination Therapy in Non-Small Cell Lung Cancer Patients Published in Investigational New Drugs
March 24, 2017 10:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., March 24, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced peer-reviewed publication of results of a randomized Phase 2 clinical study of the Company’s cancer...
BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in Tokyo
March 14, 2017 08:30 ET
|
BeyondSpring, Inc.
NEW YORK, March 14, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today...